In lung cancer, for NSCLC, METTL3 promotes autophagy by upregulating the expression of LC3B, ATG5, and ATG7, protecting drug-resistant cells from death and leading to the development of resistance to gefitinib. Here, ATG5 is linked to non-small cell lung carcinoma.